These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16787208)

  • 1. Macromolecular ensembles of internal and external fibrinolysis: the resources for enhancement of thrombolysis efficacy.
    Maksimenko AV; Tischenko EG
    Curr Med Chem; 2006; 13(14):1617-25. PubMed ID: 16787208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY; Nichols WW; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The fibrinolytic system and its activators].
    Seifried E
    Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular interactions during fibrinolysis. Search for new plasminogen activators].
    Maksimenko AV
    Mol Biol (Mosk); 1995; 29(1):38-60. PubMed ID: 7723763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activators: pharmacology and therapy.
    Holden RW
    Radiology; 1990 Mar; 174(3 Pt 2):993-1001. PubMed ID: 2137641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological potentials for activating the fibrinolytic system].
    Markwardt F
    Z Gesamte Inn Med; 1984 May; 39(10):209-13. PubMed ID: 6380126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
    Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic principles in thrombolysis: regulatory role of plasminogen.
    Rijken DC; Sakharov DV
    Thromb Res; 2001 Sep; 103 Suppl 1():S41-9. PubMed ID: 11567668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New thrombolytic drugs].
    Ferstrate M
    Kardiologiia; 1990 Feb; 30(2):120-6. PubMed ID: 2190038
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in clinical fibrinolysis.
    Hessel LW; Kluft C
    Clin Haematol; 1986 May; 15(2):443-63. PubMed ID: 2942332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remaining perspectives of mutant and chimeric plasminogen activators.
    Lijnen HR; Collen D
    Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy.
    Longstaff C; Williams S; Thelwell C
    Cardiovasc Hematol Agents Med Chem; 2008 Jul; 6(3):212-23. PubMed ID: 18673235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
    Gram J
    Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Position and developmental trends in fibrinolytic therapy].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):6-17. PubMed ID: 2427416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.